Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis. (NCT06253117)

🧪 Interventions in This Study

• Pirfenidone (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (3 Sites)

• University of Alabama at Birmingham — Birmingham, Alabama
• University of Iowa Health Care — Iowa City, Iowa
• Mayo Clinic — Rochester, Minnesota

📞 Contact the Study Coordinator

Phone: (205) 975-3593

Email: kbaig@uabmc.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Recurrent Acute Pancreatitis

• Soy Tomato Juice to Improve Outcomes in Pancreatitis — Columbus, Ohio
• Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis — Los Angeles, California

Explore by condition: All Recurrent Acute Pancreatitis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.